<DOC>
	<DOCNO>NCT02093819</DOCNO>
	<brief_summary>To investigate safety tolerability BI 416970 ass pharmacokinetics ( PK ) single rise dos BI 416970 . A objective ass influence CYP2C9 phenotype PK BI 416970 .</brief_summary>
	<brief_title>To Assess Safety , Tolerability Pharmacokinetics BI 416970 Healthy Male Volunteers</brief_title>
	<detailed_description />
	<criteria>Inclusion criterion : Healthy male accord investigator 's assessment , base complete medical history include physical examination , vital sign ( Blood Pressure , Pulse Rate ) , 12lead electrocardiogram , clinical laboratory Age 18 50 year ( incl . ) Body Mass Index 18.5 29.9 kg/m2 ( incl . ) Signed date write informed consent prior admission study accordance GCP local legislation Known genotype CYP2C9 isoenzyme Exclusion criterion : Any find medical examination ( include Blood Pressure , Pulse Rate Electrocardiogram ) deviate normal judge clinically relevant investigator Repeated measurement systolic blood pressure outside range 90140 mmHg , diastolic blood pressure outside range 5090 mmHg , pulse rate outside range 50 90 bpm Any laboratory value outside reference range investigator considers clinical relevance Any evidence concomitant disease judge clinically relevant investigator Gastrointestinal , hepatic , renal , respiratory , cardiovascular , metabolic , immunological hormonal disorder Surgery gastrointestinal tract could interfere kinetics trial medication Diseases central nervous system ( epilepsy ) , peripheral neurological disorder psychiatric disorder</criteria>
	<gender>Male</gender>
	<minimum_age>18 Years</minimum_age>
	<maximum_age>50 Years</maximum_age>
	<verification_date>February 2016</verification_date>
</DOC>